Effectiveness of guideline-recommended cardiac drugs for reducing mortality in the elderly Medicare heart failure population a retrospective, survey-weighted, cohort analysis.

Background: Heart failure (HF) management guidelines recommend that most patients with HF receive an ACE inhibitor or an angiotensin II type I receptor antagonist (angiotensin receptor blocker [ARB]) and a β-blocker (β-adrenoceptor antagonist), collectively referred to as 'cardiac drugs', based on r...

Descripción completa

Detalles Bibliográficos
Publicado en:Drugs & Aging Vol. 27; no. 10; pp. 845 - 855
Autores principales: Richardson DM, Bain KT, Diamond JJ, Novielli KD, Lee SP, Goldfarb NL
Formato: research tables/charts Journal Article
Publicado: Springer Nature 2010
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104958646&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104958646
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        1170229X
        C5B
      jtl: Drugs & Aging
      issn: 1170229X
      maglogo: N
    pubinfo:
      dt: 2010
      vid: 27
      iid: 10
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        104958646
        55833566
        10.2165/11539340-000000000-00000
        NLM20883064
        104958646
      ppf: 845
      ppct: 10
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Effectiveness of guideline-recommended cardiac drugs for reducing mortality in the elderly Medicare heart failure population a retrospective, survey-weighted, cohort analysis.
      aug:
        au:
          Richardson DM
          Bain KT
          Diamond JJ
          Novielli KD
          Lee SP
          Goldfarb NL
        affil: Center for Health Equity Research and Promotion, Philadelphia VA Medical Center, Philadelphia, Pennsylvania, USA.
      sug:
        subj:
          Heart Failure Drug Therapy
          Guideline Adherence
          Heart Failure Mortality
          Human
          Aged
          Aged, 80 and Over
          Female
          Male
          Retrospective Design
          Medicare
          Surveys
          Multivariate Analysis
          Research Methodology
          Funding Source
          Aged: 65+ years
          Aged, 80 & over
          Female
          Male
      ab: Background: Heart failure (HF) management guidelines recommend that most patients with HF receive an ACE inhibitor or an angiotensin II type I receptor antagonist (angiotensin receptor blocker [ARB]) and a β-blocker (β-adrenoceptor antagonist), collectively referred to as 'cardiac drugs', based on results from randomized controlled trials showing that these drugs reduce mortality. However, the results of randomized controlled trials may not be generalizable to the population most likely (i.e. the elderly) to receive these drugs in clinical practice. Objective: To determine the effectiveness of cardiac drugs for reducing mortality in the elderly Medicare HF population. Study Design: Retrospective, survey-weighted, cohort analysis of the 2002 Medicare Current Beneficiary Survey Cost and Use files. Participants: 12697 beneficiaries, of whom 1062 had a diagnosis of HF and 577 were eligible to receive cardiac drugs. Measurements: Association between mortality and cardiac drugs, adjusted for sociodemographics, co-morbidity and propensity to receive cardiac drugs. Results: The mortality rate among the 577 eligible beneficiaries with HF was 9.7%. The mortality rate for those receiving an ACE inhibitor or ARB alone, a β-blocker alone, or both an ACE inhibitor or ARB and a β-blocker, was 6.1%, 5.9% and 5.3%, respectively; in the absence of any of the three cardiac drugs, the mortality rate was 20.0% (p<0.0001). In multivariable analyses, mortality rates remained significantly lower for beneficiaries receiving an ACE inhibitor or ARB alone (odds ratio [OR] 0.24; 95% CI 0.11, 0.50), a β-blocker alone (OR 0.17; 95% CI 0.07, 0.41). or both an ACE inhibitor or ARB and a β-blocker (OR 0.24; 95% CI 0.10, 0.55) compared with patients who did not receive any of the three cardiac drugs. Conclusions: Use of guideline-recommended cardiac drugs is associated with reduced mortality in the elderly Medicare HF population. Providing evidence of the benefit of cardiac drugs among the elderly with HF will become increasingly important as the size of the Medicare population grows.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N